Iron chelation therapy for myelodysplastic syndrome: a systematic review and meta-analysis
The DOI matches its Crossref record; 46 of the 47 references it cites were found in a registry or an index.
Abstract
Iron overload remains a concern in myelodysplastic syndrome (MDS) patients especially those requiring recurrent blood transfusions. Whether iron chelating therapy (ICT) is beneficial to the long-term survival of myelodysplastic syndrome is still a controversial issue. Therefore, we conducted a systematic review and meta-analysis to clarify the relationship between ICT and long-term survival in patients with MDS. A total of 14 studies involving 7242 participants were identified; the outcomes revealed that for patients with MDS, ICT resulted in a lower risk of mortality compared to those with no ICT (HR 0.57; 95% CI 0.44-0.70; P < 0.001); what is more, ICT led to a lower risk of leukemia transformation (HR 0.70; 95% CI 0.52-0.93; P = 0.016). Results of subgroup analyses based on adequate ICT or any ICT, low/int-1 IPSS or unclassified IPSS and study types indicated that the ICT had a beneficial role in all these groups of patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recently, a randomized study and meta‐analysis clarified that patients who were assigned to an ICT group showed longer survival, with low risk of progression to leukemia, compared with a non‐ICT group.42, 43”
From Reactive Oxygen Species in Cancer: Current Findings and Future Directions (2021) · cites this paper as [43]
Citations
Cites
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
Shamseer, L., Moher, D., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., Shekelle, P., Stewart, L. A., & the PRISMA-P Group (2015) · BMJ · doi:10.1136/bmj.g7647 · Cited by 13,120 · cited 1×
“The present meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Meta-Analysis of Observational Studies in Epidemiology (MOOSE) guidelines [24, 25].”
MethodRevised International Prognostic Scoring System for Myelodysplastic Syndromes
Greenberg, P. L., Tuechler, H., Schanz, J., Sanz, G., Garcia-Manero, G., Solé, F., Bennett, J. M., Bowen, D., Fenaux, P., Dreyfus, F., et al. (2012) · Blood · doi:10.1182/blood-2012-03-420489 · Cited by 2,844
Porter, J., Galanello, R., Saglio, G., Neufeld, E. J., Vichinsky, E., Cappellini, M. D., Olivieri, N., Piga, A., Cunningham, M. J., Soulières, D., et al. (2008) · European Journal of Haematology · doi:10.1111/j.1600-0609.2007.00985.x · Cited by 237
Rose, C., Brechignac, S., Vassilief, D., Pascal, L., Stamatoullas, A., Guerci, A., Larbaa, D., Dreyfus, F., Beyne-Rauzy, O., Chaury, M. P., et al. (2010) · Leukemia Research · doi:10.1016/j.leukres.2009.12.004 · Cited by 195 · cited 1×
“Rose [27] 2010 France 72 55/42 97 (53/44) Pro 45/52/0/0”
Gattermann, N., Finelli, C., Porta, M. D., Fenaux, P., Ganser, A., Guerci-Bresler, A., Schmid, M., Taylor, K., Vassilieff, D., Habr, D., et al. (2010) · Leukemia Research · doi:10.1016/j.leukres.2010.03.009 · Cited by 173
List, A. F., Baer, M. R., Steensma, D. P., Raza, A., Esposito, J., Martinez-Lopez, N., Paley, C., Feigert, J., & Besa, E. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.1222 · Cited by 172
Gattermann, N., Finelli, C., Della Porta, M., Fenaux, P., Stadler, M., Guerci-Bresler, A., Schmid, M., Taylor, K., Vassilieff, D., Habr, D., et al. (2012) · Haematologica · doi:10.3324/haematol.2011.048546 · Cited by 168
Neukirchen, J., Fox, F., Kündgen, A., Nachtkamp, K., Strupp, C., Haas, R. R., Germing, U., & Gattermann, N. (2012) · Leukemia Research · doi:10.1016/j.leukres.2012.04.006 · Cited by 136
Ghoti, H., Amer, J., Winder, A., Rachmilewitz, E., & Fibach, E. (2007) · European Journal of Haematology · doi:10.1111/j.1600-0609.2007.00972.x · Cited by 109
Cited by
Reactive Oxygen Species in Cancer: Current Findings and Future Directions
Nakamura, H., & Takada, K. (2021) · Cancer Science · doi:10.1111/cas.15068 · Cited by 1,027
Iron overload-induced oxidative stress in myelodysplastic syndromes and its cellular sequelae
Kim, C. H., & Leitch, H. A. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103367 · Cited by 56
Iron overload and its impact on outcome of patients with hematological diseases
Franke, G., Kubasch, A. S., Cross, M. A., Vučinić, V., & Platzbecker, U. (2020) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100868 · Cited by 43
Complement activation and coagulopathy - an ominous duo in COVID19
Tomo, S., Kumar, K. P., Roy, D., Sankanagoudar, S., Purohit, P., Yadav, D., Banerjee, M., Sharma, P., & Misra, S. (2021) · Expert Review of Hematology · doi:10.1080/17474086.2021.1875813 · Cited by 31
From Biology to Clinical Practice: Iron Chelation Therapy With Deferasirox
Palumbo, G. A., Galimberti, S., Barcellini, W., Cilloni, D., Renzo, N. D., Elli, E. M., Finelli, C., Maurillo, L., Ricco, A., Musto, P., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.752192 · Cited by 21
Metadata
- Authors
- Liu, H., Yang, N., Meng, S., Zhang, Y., Zhang, H., & Zhang, W.
- Affiliations
- Second Affiliated Hospital of Xi'an Jiaotong University (CN)
- Corresponding author
- Zhang, Wanggang
- Venue
- Clinical and Experimental Medicine
- Published
- 2019-11-11
- Volume
- 20
- Issue
- 1
- Pages
- 1-9
- ISSN
- 1591-8890 (ISSN-L)
- 1591-9528
- OpenAlex
- W2988761910
- Cited by
- 13
- References
- 47
- Citations by year
- 2025: 3 · 2023: 1 · 2021: 6 · 2020: 3
- FWCI
- 0.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Clinical and Experimental Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Shaanxi International Scientific Research Cooperation and Exchange Program (2016KW-020)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Keywords
- iron chelation therapy, myelodysplastic syndrome, iron overload, blood transfusion, mortality, leukemic transformation, long-term survival, International Prognostic Scoring System, subgroup analysis
- MeSH terms
- Humans, Iron, Myelodysplastic Syndromes, Chelation Therapy, Survival Analysis, Treatment Outcome, Iron Overload
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Iron chelation therapy for myelodysplastic syndrome: a systematic review and meta-analysis. https://app.cochat.ai/papers/10.1007/s10238-019-00592-5
- The paper
- Liu, H., Yang, N., Meng, S., Zhang, Y., Zhang, H., & Zhang, W. (2020). Iron chelation therapy for myelodysplastic syndrome: a systematic review and meta-analysis. Clinical and Experimental Medicine. https://doi.org/10.1007/s10238-019-00592-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.